COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH ABOBOTULINUMTOXINA COMPARED TO BEST SUPPORTIVE CARE IN PATIENTS WITH UPPER LIMB SPASTICITY IN SWEDEN

被引：0
|
作者：
Forsmark, A. [1 ]
Danchenko, N. [2 ]
Ertzgaard, P. [3 ]
Lundkvist, J. [4 ]
Rosengren, L. [5 ]
机构：
[1] Nord Hlth Econ, Gothenburg, Sweden
[2] Ipsen Pharma, Boulogne, France
[3] Linkoping Univ, Fac Hlth Sci, Linkoping, Sweden
[4] Ipsen Pharma, Uppsala, Sweden
[5] Ipsen Pharma, Kista, Sweden
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2024
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND58
引用
收藏
页码：S338 / S339
页数：3
相关论文
共 50 条
  • [41] A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy
    Wolters, Sharon
    Carpay, Johannes A.
    Pronk, Marja H.
    Zuurbier, Karin W. M.
    Driessen, Maurice T.
    Lyras, Leonidas
    Postma, Maarten J.
    BMC NEUROLOGY, 2024, 24 (01)
  • [42] Cost-Analysis of the Use of IncobotulinumtoxinA and AbobotulinumtoxinA for the Treatment of Post-Stroke Upper Limb Spasticity Based on Recommended Dosing for Muscles and Clinical Patterns
    Gendron, M. E.
    Vezina, D.
    MOVEMENT DISORDERS, 2020, 35 : S589 - S589
  • [43] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Spain
    Maroto, P.
    Villavicencio, H.
    Pinol, C.
    Urruticoechea, L.
    VALUE IN HEALTH, 2006, 9 (06) : A280 - A280
  • [44] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma.
    Gao, X.
    Reddy, P.
    Dhanda, R.
    Gondek, K.
    Yeh, Y. C.
    Stadler, W. M.
    Jonasch, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 242S - 242S
  • [45] Cost-Analysis of the Use of IncobotulinumtoxinA and AbobotulinumtoxinA for the Treatment of Post-Stroke Upper Limb Spasticity Based on Recommended Dosing for Muscles and Clinical Patterns
    Gendron, Marie-Eve
    Vezina, Denis
    NEUROLOGY, 2020, 94 (15)
  • [46] COST-EFFECTIVENESS OF INCOBOTULINUMTOXIN-A IN THE LONGER-TERM MANAGEMENT OF POST-STROKE SPASTICITY OF THE UPPER LIMB
    Makino, K.
    Tilden, D.
    Guamieri, C.
    Mudge, M.
    Baguley, I
    VALUE IN HEALTH, 2017, 20 (09) : A724 - A724
  • [47] Economic evaluation of sorafenib versus best supportive care in advanced renal cell carcinoma: An updated cost-effectiveness analysis
    Gao, X.
    Shah, S.
    Reddy, P.
    Gondek, K.
    Pashos, C. L.
    VALUE IN HEALTH, 2008, 11 (03) : A61 - A61
  • [48] COST-EFFECTIVENESS ANALYSIS OF SORAFENIB ASSOCIATED TO BEST SUPPORTIVE CARE (BSC) VERSUS BEST SUPPORTIVE CARE ALONE IN THE SECOND LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
    Teich, V
    Fernandes, R. A.
    Schiola, A.
    VALUE IN HEALTH, 2009, 12 (03) : A42 - A42
  • [49] Cost-effectiveness analysis of atorvastatin compared to simvastatin treatment in Greece
    Yfantopoulos, J.
    Papagiannopoulou, V.
    ARCHIVES OF HELLENIC MEDICINE, 2007, 24 (05):
  • [50] Cost minimization analysis of BoNT-As in the treatment of upper limb spasticity and cervical dystonia
    Bartolomei, Luigi
    Bentivoglio, Anna Rita
    Bizzarini, Massimo
    Caglioni, Patrizia Maria
    Cerbarano, Luana
    Frontoni, Marco
    Lus, Giacomo
    Majorana, Giovanni
    Nassetti, Stefania Alessandra
    Osio, Maurizio
    Ravasio, Roberto
    Ravenni, Roberta
    Santoro, Antonio
    Smania, Nicola
    Torlizzi, Flavia
    Valvo, Sebastiana Claudia
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2016, 3 (01) : 23 - 31
12345